FDA Approves Auvelity for Alzheimer Disease-Related Agitation

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

WEDNESDAY, May 6, 2026 -- The U.S. Food and Drug Administration has approved the expanded use of Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat adults with agitation associated with dementia due to Alzheimer disease.

Auvelity was initially approved in 2022 to treat major depressive disorder in adults and is the first nonantipsychotic approved for agitation associated with dementia due to Alzheimer disease.

The approval was based on a five-week trial in which participants received either Auvelity or a placebo. Those randomly assigned to Auvelity showed a significantly greater change in the primary end point of total score of the Cohen-Mansfield Agitation Inventory based on caregiver reports. Among those who achieved a response, those who were randomly assigned to continue Auvelity treatment had a significantly longer time to relapse of agitation symptoms versus patients subsequently assigned to receive placebo.

"Auvelity was found to be efficacious for treating agitation in Alzheimer’s disease in two randomized trials and now represents an additional option to address one of the most difficult sequelae of the disease, especially as it progresses," Tracy Beth Hoeg, M.D., Ph.D., from the FDA Center for Drug Evaluation and Research, said in a statement. "We hope this approval will provide meaningful benefit to patients, their families, and caregivers."

Expanded approval of Auvelity was granted to Axsome Therapeutics.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-07 09:32

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords